Format

Send to

Choose Destination
Curr Opin Infect Dis. 2019 Dec;32(6):559-564. doi: 10.1097/QCO.0000000000000603.

Candida auris: what have we learned so far?

Author information

1
Infectious Diseases Department, Hillcrest Medical Center, Tulsa, Oklahoma.
2
Division of Infectious Diseases, University of Texas McGovern Medical School, Houston, Texas, USA.

Abstract

PURPOSE OF REVIEW:

The increasing prevalence of fungal infections due to Candida species has been well described in critically ill patient populations, but in recent years a new species, Candida auris has received attention from the medical community worldwide. We aim to summarize the current knowledge related to C. auris, as new identification techniques, novel antifungal agents and more experience with outbreak management have been published in the past few years.

RECENT FINDINGS:

C. auris has been described in several countries, arising independently in separate clades. Its resistance to multiple antifungals and persistent colonization of patients and medical surfaces have become a therapeutic and infection control challenge. Recent elucidation of some of the molecular mechanisms related to pathogenicity and studies of in-vitro efficacy of novel antifungal agents can better guide therapy.

SUMMARY:

As C. auris continues to cause outbreaks worldwide, newer, and more efficient identification techniques, novel antifungals, and more knowledge in effective infection control techniques will allow better clinical outcomes in the management and control of invasive fungal disease.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center